ESMO-ESTRO 共识:放疗联合 CDK4/6、HER2、PARP 或 mTOR 抑制剂的安全性
ESMO 与 ESTRO 通过系统综述和改良德尔菲法,由 18 位国际专家对 74 个临床场景投票,形成放疗联合 CDK4/6、抗 HER2 单抗、PARP 或 mTOR 抑制剂的安全性共识声明。系统综述筛选 1341 条记录,最终纳入 107 项研究,两轮投票后全部 74 条场景特异性安全声明达成一致。结论认为抗 HER2 单抗联合放疗的预期联合毒性常较低,而多数 CDK4/6、PARP 或 mTOR 抑制剂场景建议谨慎。
要点
- 抗 HER2 单抗联合放疗的预期联合毒性常较低。
- 多数 CDK4/6、PARP 或 mTOR 抑制剂联合放疗场景建议谨慎。
- 共识覆盖 74 个药物类别与照射部位组合的临床场景。
核心结论
- 抗 HER2 单抗联合放疗的预期联合毒性常较低。
- 多数 CDK4/6、PARP 或 mTOR 抑制剂联合放疗场景建议谨慎。
研究设计与样本
- ESMO 与 ESTRO 开展系列系统综述,并采用多学科、肿瘤不可知、循证改良德尔菲共识方法。
- 由 18 位国际专家进行两轮数字投票,系统评估不同药物类别与照射部位,共 74 个临床场景。
主要发现
- 系统综述共筛选 1341 条记录,最终 107 项研究纳入综述和文献数据库。
- 两轮德尔菲投票后,全部 74 条场景特异性安全声明均达成一致。
关键数值与推荐
- 针对抗 HER2 单抗联合放疗,预期联合毒性常较低。
- 针对多数 CDK4/6、PARP 或 mTOR 抑制剂联合放疗场景,建议谨慎。
临床怎么用
- 放疗联合抗 HER2 单抗时可预期联合毒性常较低。
- 放疗联合 CDK4/6、PARP 或 mTOR 抑制剂时,多数场景应谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While combining radiotherapy (RT) with targeted agents or immunotherapy may improve outcomes, it may also increase toxicity. High-quality toxicity data and multidisciplinary, evidence-based guidelines on the combination of these treatment modalities are scarce. DESIGN: The European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy and Oncology (ESTRO) developed a series of systematic reviews with multidisciplinary, tumor-agnostic, evidence-based Delphi consensus statements regarding the safety of combining RT with targeted agents or immunotherapy. The current study addresses the safety of combining RT with CDK4/6 inhibitors, anti-HER2 monoclonal antibodies, PARP inhibitors, or mTOR-inhibitors. During the modified Delphi process, two digital voting rounds were organized with 18 international experts. By systematically evaluating the different drug classes and irradiated areas, 74 clinical scenarios were assessed. Safety statements were formulated for all scenarios, based on the evidence from the systematic literature reviews. RESULTS: A total of 1,341 records were screened during the systematic literature reviews, of which 107 studies were ultimately included in the final reviews and the literature database. After two Delphi voting rounds, agreement was reached on all 74 scenario-specific safety statements. CONCLUSIONS: The expected combined toxicity is often low for anti-HER2 monoclonal antibodies. For most scenarios with CDK4/6, PARP, or mTOR inhibitors, exercising caution is recommended.
引用
- van Aken ESM, Gandhi AK, O'Cathail SM, et al. ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors. Radiother Oncol. 2025. PMID: 41389857. doi:10.1016/j.radonc.2025.111330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。